Bacteriophages: A therapy concept against multi-drug-resistant bacteria

Surgical Infections

Volumn 19, Issue 8, 2018, Pages 737-744

  Rohde, Christine ^a   Wittmann, Johannes ^a   Kutter, Elizabeth ^b  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b EVERGREEN STATE COLLEGE   (United States)

Author keywords

antimicrobial drug resistance; bacteriophage therapy; bacteriophages; ESKAPE bacteria; microbiome; nosocomial infections

Indexed keywords

ANTIBIOTIC AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIOPHAGE; CELL LYSATE; HUMAN; IMMUNE RESPONSE; MICROBIOME; MULTIDRUG RESISTANCE; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; VIRUS PURIFICATION; ANIMAL; MEDICAL RESEARCH; MICROBIOLOGY; PROCEDURES; TRENDS;

ANIMALS; BACTERIAL INFECTIONS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PHAGE THERAPY;

EID: 85058363578     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2018.184     Document Type: Article

References (76)

1. Aryitey W. Protecting the last resort. Detecting antimicrobial resistance to emergency antibiotic colistin. The Pathologist Feb 2017.
2. Yao X, Doi Y, Zeng L, et al. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis 2016;16:288-289.
3. Antimicrobial Resistance Global Report on surveillance. World Health Organization 2014.
4. Carlet J. The world alliance against antibiotic resistance: Consensus for a declaration. Clin Infect Dis 2015;60:1837-1841.
5. Debarbieux L, Pirnay JP, Verbeken G, et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 2016;363(2).
6. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015; 517:455-459.
7. Outterson K, Rex JH, Jinks T, et al. Accelerating global innovation to address antibacterial resistance: Introducing CARB-X. Nat Rev Drug Discov 2016;15:589-590.
8. Tamayo-Legorreta E, Turrubiartes-Martinez E, Garza- Ramos U, et al. Outbreak caused by blaOXA-72-producing Acinetobacter baumannii ST417 detected in clinical and environmental isolates. Microb Drug Resist 2016;22:129-133.
9. Hall JP, Wood AJ, Harrison E, Brockhurst MAL. Source-sink plasmid transfer dynamics maintain gene mobility in soil bacterial communities. Proc Natl Acad Sci U S A 2016; 113:8260-8265.
10. Dötsch A, Schniederjans M, Khaledi A, et al. The Pseudomonas aeruginosa transcriptional landscape is shaped by environmental heterogeneity and genetic variation. MBio 2015;6:e00749.
11. Kittler S, Wittmann J, Mengden R, et al. The use of bacteriophages as One-Health approach to reduce multidrugresistant bacteria. Sustainable Chemistry and Pharmacy 2016; 5:80-83.
12. Piffaretti JC. Antibiotic resistance: The emergence of plasmid-mediated colistin resistance enhances the need of a proactive one-health approach. FEMS Microbiol Lett 2016; 363:fnw034.
13. Califf K, Gonzalez A, Knight R, Caporaso JG. The human microbiome: Getting personal. Microbe 2014;9:410-415.
14. Knight DR, Squire MM, Collins DA, Riley TV. Genome analysis of Clostridium difficile PCR Ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission. Front Microbiol 2017;7:2138.
15. Krause G. Changing infection patterns. Dtsch Arztebl Int 2017;114:849-850.
16. Wahida A, Ritter K, Horz HP. The Janus-face of bacteriophages across human body habitats. PLoS Pathog 2016; 12:e1005634.
17. Manrique P, Dills M, Young MJ. The human gut phage community and its implications for health and disease. Viruses 2017;9(6).
18. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016;8:51.
19. Bakhshinejad B, Ghiasvand S. Bacteriophages in the human gut: Our fellow travelers throughout life and potential biomarkers of health or disease. Virus Res 2017;240:47-55.
20. Erez Z, Steinberger-Levy I, Shamir M, et al. Communication between viruses guides lysis-lysogeny decisions. Nature 2017;541:488-493.
21. Asadulghani M, Ogura Y, Ooka T et al. The defective prophage pool of Escherichia coli O157: Prophage-prophage interactions potentiate horizontal transfer of virulence determinants. Plos Pathog 2009;5:e1000408.
22. Kim EJ, Yu HJ, Lee JH, et al. Replication of Vibrio cholerae classical CTX phage. Proc Natl Acad Sci U S A 2017; 114:2343-2348.
23. Fortier LC, Sekulovic O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 2013; 4:354-365.
24. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 2011;1:31-45.
25. Colavecchio A, Cadieux B, Lo A, Goodridge LD. Bacteriophages contribute to the spread of antibiotic resistance genes among foodborne pathogens of the Enterobacteriaceae family-A review. Front Microbiol 2017;8:1108.
26. Feiner R, Argov T, Rabinovich L, et al. A new perspective on lysogeny: Prophages as active regulatory switches of bacteria. Nat Rev Microbiol 2015; 3:641-650.
27. Canchaya C, Proux C, Fournous G, et al. Prophage genomics. Microbiol Mol Biol Rev 2003;67:238-276.
28. Touchon M, Bernheim A, Rocha EP. Genetic and lifehistory traits associated with the distribution of prophages in bacteria. ISME J 2016;10:2744-2754.
29. Chen VE, Fischbach MA, Belkaid Y. Skin microbiota- host interactions. Nature 2018;553:427-436.
30. Reizner W, Hunter JG, O'Malley NT, et al. A systematic review of animal models for Staphylococcus aureus osteomyelitis. Eur Cell Mater 2014;27:196-212.
31. Twort F. An investigation on the nature of ultra-microscopic viruses. Lancet 1915;186.
32. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011;1:66-85.
33. Chanishvili N (ed). A Literature Review of the Practical Application of Bacteriophage Research. Hauppauge, New York: Nova Science Publishers, 2012.
34. Hoyle N, Zhvaniya P, Balarjishvili N, et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: A case report. Res Microbiol 2018 May 16. Epub ahead of print.
35. Zhvania P, Hoyle NS, Nadareishvili L, et al. Phage therapy in a 16-year-old boy with Netherton syndrome. Front Med 2017;4:94.
36. Mieȩdzybrodzki R, Borysowski J, Kłak M, et al. In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. Biomed Res Int 2017;2017:3612015.
37. Borysowski J, Mieȩdzybrodzki R, Wierzbicki P, et al. A3R phage and Staphylococcus aureus lysate do not induce neutrophil degranulation. Viruses 2017;Feb 21;9.
38. Łusiak-Szelachowska M, Z_ aczek M, Weber-Daȩbrowska B, et al. Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbiol. 2017;12:109-117.
39. Jennes S, Merabishvili M, Soentjens P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury - A case report. Crit Care 2017;21:129.
40. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: A preliminary report of efficacy. Clin Otolaryngol 2009;34:349-357.
41. Fong SA, Drilling A, Morales S, et al. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol 2017;7:418.
42. Mendes JJ, Leandro C, Corte-Real S, et al. Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen 2013;21:595-603.
43. Fish R, Kutter E, Wheat G, et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials. In: Azeredo J, Sillankorva S (eds). Bacteriophage Therapy. Methods in Molecular Biology. 2018; vol 1693. New York: Humana Press.
44. Markoishvili K, Tsitlanadze G, Katsarava R, et al. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol 2002;41:453-458.
45. Harper DR, Parracho HM, Walker J, et al. Bacteriophages and biofilms. Antibiotics 2014;3(3).
46. Rossmann FS, Racek T, Wobser D, et al. Phage-mediated dispersal of biofilm and distribution of bacterial virulence genes is induced by quorum sensing. PLOS Pathog 2015; 11:e1004653.
47. Barr JJ, Auro R, Furlan M, et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci U S A 2013;110:10771-10776.
48. Nguyen S, Baker K, Padman BS, et al. Baceriophage transcytosis provides a mechanism to cross epithelial cell layers. MBio 2017;8(6).
49. Young R. Phage lysis: Do we have the hole story yet? Curr Opin Microbiol 2013;16:790-797.
50. O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009;33:801-819.
51. Gravitz L. Turning a new phage. Nat Med 2012;18:1318-1320.
52. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012; 7:1147-1171.
53. Sharma U, Paul VD. Bacteriophage lysins as antibacterials. Crit Care 2017;21:99.
54. Fischetti VA. Development of phage lysins as novel therapeutics: A historical perspective. Viruses 2018;10(6).
55. Gerstmans H, Rodríguez-Rubio L, Lavigne R, Briers Y. From endolysins to Artilysins: Novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans 2016;44:123-128.
56. Kutter E, Bryan D, Ray G, et al. From host to phage metabolism: Hot tales of phage T4's takeover of E. coli. Viruses 2018;10:387.
57. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: Treatment of human infections. Curr Pharm Biotechnol 2010;11:69-86.
58. Kurzepa A, Dabrowska K, Skaradzinski G, Górski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med 2009;9:93-100.
59. Kaur T, Nafissi N, Wasfi O, et al. Immunocompatibility of bacteriophages as nanomedicines. J Nanotechnology 2012; 247427.
60. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010;8:317-327.
61. Chan BK, Sistrom M, Wertz JE, et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016;6:26717.
62. Guttman B, et al. Basic phage biology. In: Kutter E, Sulakvelidze A (eds). Bacteriophages: Biology and Applications. Boca Raton, FL: CRC Press, 2005:29-66.
63. Kvachadze L, Balarjishvili N, Meskhi T, et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 2011; 4:643-650.
64. Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 2016;363(3).
65. Pirnay JP, Blasdel BG, Bretaudeau L, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res 2015;32:2173-2179.
66. Verbeken G, Pirnay JP, Lavigne R, et al. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz) 2014;62:117-129.
67. Cooper CJ, Khan Mirzaei M. Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 2016;7:1209.
68. Witzenrath M. Time for tailored antimicrobials: Adapted bacteriophages in the ICU. Crit Care Med 2015;43:1346-1347.
69. Akhter S, Aziz RK, Edwards RA. PhiSpy: A novel algorithm for finding prophages in bacterial genomes that combines similarity- and composition-based strategies. Nucleic Acids Res 2012;40:e126.
70. Arndt D, Marcu A, Liang Y, Wishart DS. PHAST, PHASTER and PHASTEST: Tools for finding prophage in bacterial genomes. Brief Bioinform 2017. Epub ahead of print.
71. Rohde C, Resch G, Pirnay JP, et al. Expert opinion on three phage therapy related topics: Bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses 2018;10(4).
72. Fauconnier A. Regulating phage therapy. EMBO Rep 2017; 18:198-200.
73. Sybesma W, Pirnay JP. Silk route to the acceptance and reimplementation of bacteriophage therapy. Biotechnol J 2016;11:595-600.
74. Aminov R, Caplin J, Chanishvili N, et al. Application of bacteriophages. Microbiol Aust 2017;38:63-66.
75. Servick K. U.S. center will fight infections with viruses. Science 2018;360:1280-1281.
76. Pirnay JP, Verbeken G, Ceyssens PJ, et al. The magistral phage. Viruses 2018;10(2).